Evan Y. Snyder earned his MD and PhD (in neuroscience) from the University of Pennsylvania in 1980 as a member of NIH’s Medical Scientist Training Program (MSTP). He had also studied psychology and linguistics at the University of Oxford. After moving to Boston in 1980, he completed residencies in pediatrics and neurology as well as a clinical fellowship in Neonatal-Perinatal Medicine at Children’s Hospital-Boston, Harvard Medical School. He also served as Chief Resident in Medicine (1984-1985) and Chief Resident in Neurology (1987) at Children’s Hospital-Boston. In 1989, he became an attending physician in the Department of Pediatrics (Division of Newborn Medicine) and Department of Neurology at Children’s Hospital-Boston, Harvard Medical School. From 1985-1991, concurrent with his clinical activities, he conducted postdoctoral research as a fellow in the Department of Genetics, Harvard Medical School. In 1992, Dr. Snyder was appointed an instructor in neurology (neonatology) at Harvard Medical School and was promoted to assistant professor in 1996. He maintained lab spaces in both Children’s Hospital-Boston and at Harvard Institutes of Medicine/Beth-Israel Deaconess Medical Center. In 2003, Dr. Snyder was recruited to Sanford Burnham Prebys as Professor and Director of the Program in Stem Cell and Regenerative Biology. He then inaugurated the Stem Cell Research Center (serving as its founding director) and initiated the Southern California Stem Cell Consortium. Dr. Snyder is a Fellow of the American Academy of Pediatrics (FAAP). He also received training in Philosophy and Linguistics at Oxford University.
Related Disease: Breast Cancer
Andrei Osterman is a Professor in the Immunity and Pathogenesis Program Program at the Infectious and Inflammatory Disease Center of Sanford Burnham Prebys (since August 2003). He received his doctorate from Moscow State University in 1983, did postdoctoral work UT Southwestern Medical Center, and held the position of the Director and then Vice President of Research at Integrated Genomics in 1999-2003. Dr. Osterman is one of the founders of the Fellowship for Interpretation of Genomes (FIG), a nonprofit research organization that launched the Project to Annotate 1,000 Genomes in 2003. FIG provides the open-source integration of all publicly available genomes and tools for their comparative analysis, annotation, and metabolic reconstruction.
Select Publications
Showing 3 of 3“Cancer is one the main causes of death in the US. Our research is focused on understanding how we can harness the power of our immune system to attack and kill cancer cells and cure patients. I chose to join Sanford Burnham Prebys because of their collaborative research culture and state-of-the- art core facilities. I believe that teamwork is the foundation of scientific breakthroughs, and the Institute provides a perfect supportive and friendly environment to achieve this.”
Originally from the Netherlands, Kelly received her BS and MS from Utrecht University, and performed her PhD studies at the Netherlands Cancer Institute in Amsterdam working with Prof. Karin de Visser studying the role of the immune system in the metastatic spread of breast cancer. For her postdoctoral training, Kelly joined the lab of Prof. Max Krummel at the University of California San Francisco to study how tumor-associated myeloid cells affect anti-tumor T cell responses. Kelly is currently setting up her independent research team at Sanford Burnham Prebys.
Education
2016-2023: Postdoctoral Training, University of California San Francisco (Mentor: Prof. Max Krummel, focus on immune evasive cancer)
2017: PhD, Netherlands Cancer Institute Amsterdam/ Leiden University (Mentor: Prof. Karin de Visser, focus on role immune system in breast cancer metastasis, 2011-2016)
2011: MS, Biomedical Sciences, Utrecht University, Netherlands
2008: BS, Biology, Utrecht University, Netherlands
Honors and Recognition
2022: Selected Attendee for SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute
2022: Selected Attendee for Arthur and Sandra Irving Cancer Immunology Symposium
2022: Ray Owen Poster Award for Outstanding Poster Presentation at 60th Midwinter Conference for Immunologists at Asilomar (sponsored by AAI)
2020-2022: Parker Scholar Award awarded by the Parker Institute for Cancer Immunotherapy (PICI)
2018: Honorable Mention of poster presentation at UCSF/UCB/UCM Immunology Retreat
2018: Poster presentation ‘Excellence in Research Award’ awarded by the National Philanthropic Trust
2017-2019: NWO Rubicon postdoctoral fellowship awarded by the Netherlands Organization for Scientific Research (NWO)
2015: Best presentation award at the annual Tumor Cell Biology meeting of the Dutch Cancer Society (KWF)
2014: Travel scholarship awarded by the Dutch Foundation for Pharmacological Sciences (NSFW)
2010: Master scholarship awarded by the Dutch Cancer Society (KWF)
Memberships
2022-present: Society for Immunotherapy of Cancer (SITC)
2020-present: Parker Institute for Cancer Immunotherapy (PICI)
2012-present: American Association for Cancer Research (AACR)
Select Publications
Showing 3 of 3Emerling received her B.A. from the University of California Santa Cruz and her PhD in molecular and cellular biology from Northwestern University. Emerling did her postdoctoral training at Harvard Medical School. She then became an Instructor of Cancer Biology in Medicine at Weill Cornell Medical College in New York City, where she continued her research on lipid kinase signaling and cancer metabolism. In August 2016, Brooke joined the faculty at Sanford Burnham Prebys Medical Discovery Institute as an Assistant Professor in the Cancer Metabolism and Signaling Networks Program.
Funding Awards and Collaborative Grants
Breast Cancer Research Foundation – AACR Career Development Award for Translational Breast Cancer Research
Mary Kay Foundation Innovative Translational Grant Award
Department of Defense Breast Research Program Breakthrough Award
Honors and Recognition
2014: NextGen Star – AACR Early-Career Speaker Award
2013-2016: Mastercard Ajay Banga Scientist Award
2013: AACR – Aflac Travel Fellowship Award
Press Release: Study offers new approach to starve p53 deficient tumors
9/25/18 Public Lecture – SBP Insights: Breast Cancer – Register Here
Select Publications
Showing 3 of 3Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.
The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis.
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
Nicholas Cosford, PhD has served on the Sanford Burnham Prebys Board of Trustees since 2023. He is the first faculty member to do so.
Cosford joined the Sanford Burnham Prebys faculty in 2008 as an associate professor. In 2013, he became a full professor. His lab investigates the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. With a specific focus on the discovery and optimization of compounds that might treat cancer, central nervous system diseases and infectious diseases.
Prior to joining Sanford Burnham Prebys in 2005, Cosford worked in both the biotechnology and pharmaceutical industries. At Sibia Neurosciences and at Merck Research Laboratories, he directed multidisciplinary research teams focused on small-molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase, including a nicotinic agonist (Altinicline) from research to Phase II clinical trials for treating Parkinson’s disease.
He is an author of more than 90 peer-reviewed, published scientific papers, and has been issued more than 40 issued patents, with an additional 40 patent applications pending.
Cosford has a Bachelor of Science degree in chemistry from the University of Bath in England and Doctor of Philosophy degree in organic chemistry from Emory University in Atlanta, GA.